Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma

Sponsor
Swiss Cancer Institute
Study ID
NCT00003280
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which treatment regimen is more effective for lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of rituximab in treating patients who have follicular or mantle cell lymphoma.

Key Dates

Start date
Jan 31, 1998
Status verified
May 2019
Primary completion
Mar 31, 2002
Completion
Mar 31, 2002

Study Design

Enrollment
240 participants (estimated)
Allocation
RANDOMIZED
Primary purpose
TREATMENT

Related Studies